To include your compound in the COVID-19 Resource Center, submit it here.

Branching out

How Regeneron is using deals to enter new disease areas outside its pipeline

Decibel Therapeutics Inc. and Regeneron Pharmaceuticals Inc. have embarked on a deal that gives the smaller company a suite of technologies it could not build itself, while giving the big cap a stake in a new therapeutic area it wouldn’t have entered on its own.

The collaboration at the deal’s heart is unusual, and is part of the big cap’s strategy to deploy its technologies into new therapeutic areas without losing focus or smothering its smaller partners.

“They prized our independence as much as we prized our independence,” said Decibel President and CEO Steven Holtzman.

Regeneron and Decibel scientists will work side by side on Decibel’s discovery and preclinical programs in hearing loss and tinnitus,

Read the full 1131 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers